Adverum Biotechnologies Inc
NASDAQ:ADVM 11:05:40 AM EDT
Earnings Announcements
Adverum Biotechnologies Reports Fourth Quarter And Full Year 2021 Financial Results
Published: 03/29/2022 20:36 GMT
Adverum Biotechnologies Inc (ADVM) - Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results.
Q4 Loss per Share $0.35.
Adverum Biotechnologies- Cash, Cash Equivalents, Short-term Investments Were $305.2 Million As of Dec 31, 2021, Compared to $332.7 Million As of Sept 30, 2021.
Adverum Biotechnologies - Expects Year-end Cash Position to Fund Operations Into 2024.
Q4 Loss per Share $0.35.
Adverum Biotechnologies- Cash, Cash Equivalents, Short-term Investments Were $305.2 Million As of Dec 31, 2021, Compared to $332.7 Million As of Sept 30, 2021.
Adverum Biotechnologies - Expects Year-end Cash Position to Fund Operations Into 2024.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.34
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.36
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.34
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.36
More details on our Analysts Page.